Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Pharmaceuticals industry for Tuesday, May 13, 2025. Let’s take ...

Momentum is building for PROTAC treatments that eliminate disease-causing proteins, including those responsible for difficult ...

Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Fintel reports that on May 5, 2025, Truist Securities downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Buy to Hold.

New Haven-based Arvinas will lay off 131 employees, with 92 in Connecticut, as part of a major workforce reduction.

In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. Novo Nordisk, Roche, ...

On Friday, Arvinas Inc. (NASDAQ:ARVN) stock rating was downgraded by TD Cowen from Buy to Hold following the announcement that partner Pfizer (NYSE:PFE) has canceled the 1L and 2L vepdeg/CDK4(6) ...

Pfizer holds 3,458K shares representing 5.03 ... The firm decreased its portfolio allocation in ARVN by 20.78% over the last quarter. Arvinas Background Information (This description is provided ...

Arvinas, Inc. (NASDAQ ... over $1 billion in cash and two significant license/collaboration agreements. With Pfizer, ARVN is eligible to receive up to $1.4 billion of payments upon the approval ...